Home Newsfeeds UPDATE: Arhaus Q2 Adj. EPS $0.28 Beats $0.12 Estimate

UPDATE: Arhaus Q2 Adj. EPS $0.28 Beats $0.12 Estimate

Arhaus (NASDAQ:ARHS) reported quarterly earnings of $0.28 per share which beat the analyst consensus estimate of $0.12 by 133.33 percent.

byBenzinga Newsdesk

August 11, 2022

1 minute read

Arhaus (NASDAQ:ARHS) reported quarterly earnings of $0.28 per share which beat the analyst consensus estimate of $0.12 by 133.33 percent.

‘Tesla Is On Pace For A Record Quarter’ – Electrek

By Happy Mohamed

March 28, 3:27 PM

https://electrek.co/2023/03/28/tesla-tsla-on-pace-record-quarter/ Tesla (TSLA) appears to be on pace for a record quarter for deliveries led by solid performance in the US, China, and Norway. At Electrek, we love

TSLA

B. Riley Securities Maintains Buy on Matthews International, Lowers Price Target to $45

By Benzinga Newsdesk

July 20, 9:46 AM

B. Riley Securities analyst Liam Burke maintains Matthews International (NASDAQ:MATW) with a Buy and lowers the price target from $50 to $45.

MATW

RenovoRx Engages Oklahoma University Health As First Clinical Site In Preparation For The Pivotal Phase III CouGar Clinical Trial In Bile Duct Cancer

By Benzinga Newsdesk

December 21, 9:33 AM

This study will be the Second Clinical Trial Evaluating RenovoGem™, a Combination Drug-Device Product, in a Difficult-to-Access Solid Tumor CancerRenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a

RNXT

Movers
News

What’s Going On With SoFi Technologies Stock After Earnings?

By Erica Kollmann

April 30, 3:14 PM

Despite the better-than-expected results, Sofi shares are dipping lower Tuesday after falling 10% on Monday. Following the print, Wedbush analyst David Chiaverini reiterated Sofi with an Underperform and maintained a $3 price target on the stock. Needham reiterated its Buy rating and maintained a $10 price target.

SOFI

UPDATE: Arhaus Q2 Adj. EPS $0.28 Beats $0.12 Estimate

Related Posts

‘Tesla Is On Pace For A Record Quarter’ – Electrek

B. Riley Securities Maintains Buy on Matthews International, Lowers Price Target to $45

RenovoRx Engages Oklahoma University Health As First Clinical Site In Preparation For The Pivotal Phase III CouGar Clinical Trial In Bile Duct Cancer

What’s Going On With SoFi Technologies Stock After Earnings?